<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49530">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461420</url>
  </required_header>
  <id_info>
    <org_study_id>P00013300</org_study_id>
    <secondary_id>1U54NS092090-01</secondary_id>
    <nct_id>NCT02461420</nct_id>
  </id_info>
  <brief_title>Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome</brief_title>
  <official_title>Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phelan-McDermid Syndrome Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to comprehensively characterize PMS using standardized medical,
      cognitive, and behavioral measures and to track the natural history of the syndrome using
      repeated longitudinal assessments. In addition, this study will be aiming to identify
      biomarkers using neuroimaging, including difusion tensor imaging and identify genetic
      factors which contribute to diverse phenotypes in patients with PMS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phelan-McDermid syndrome (PMS) or 22q13 Deletion syndrome, caused by a loss of one copy of
      the SHANK3 gene, is characterized by global developmental delay/intellectual disability,
      motor skills deficits, delayed or absent speech, and autism spectrum disorder. The goal of
      this study is to understand more about the PMS phenotype and the biological pathways
      associated with ID and ASD in the disorder, and to establish the foundation for future
      clinical trials in PMS and in other ID/ASD-associated disorders that share signaling
      pathways with PMS.

      Individuals with PMS will be asked to participate in this study if they are between the ages
      of 3 to 21 years of age with pathogenic deletions or mutations of the SHANK3 gene at time of
      enrollment. Both males and females will be asked to participate. Additionally, to be
      eligible for study participation, individuals' primary communicative language must be
      English. Parents and unaffected siblings may also be asked to consent to have blood drawn
      for analysis.

      The study involves 5 visits (3 on site visits ) over 2 years. Study visits involve a
      physical exam, medical history questions, blood work and neuropsychological assessments.
      Individuals who have certain clinically indicated procedures (i.e. MRI, EEG, etc.) due will
      have them done as part of the research study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global cognitive ability at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Using Mullen Scales for Early Learning or Stanford Binet-5 to measure global cognitive ability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in adaptive behavior at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Using Vineland Adaptive Behavior Scales to measure adaptive behavior</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in language abilities at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Using composite of Mullen Subscales, Vineland Subscales and Macarthur Bates Communication Developmental Inventory to measure language</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in motor functioning at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Using composite of Mullen Subscales and Vineland Subscales to measure motor functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in autism symptoms at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Using composite of Autism Diagnostic Observation Schedule and Repetitive Behavior Scales-Revised to measure autism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in global cognitive ability at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Using Mullen Scales for Early Learning or Stanford Binet-5 to measure global cognitive ability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in adaptive behavior at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Using Vineland Adaptive Behavior Scales to measure adaptive behavior</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change is language abilities at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Using composite of Mullen Subscales, Vineland Subscales and Macarthur Bates Communication Developmental Inventory to measure language</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in motor functioning at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Using composite of Mullen Subscales and Vineland Subscales to measure motor functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in autism symptoms at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Using composite of Autism Diagnostic Observation Schedule and Repetitive Behavior Scales-Revised to measure autism</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Phelan-McDermid Syndrome</condition>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Intellectual Disability</condition>
  <arm_group>
    <arm_group_label>Phelan-McDermid Syndrome</arm_group_label>
    <description>Phelan-McDermid Syndrome</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood draw for future correlative studies in the PMS Biorepository of the Developmental
      Synaptopathies Consortium
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        90 subjects with PMS will be enrolled across the 4 sites for this study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals 3 to 21 years of age with pathogenic deletions or mutations of the SHANK3
             gene

          -  English speaking individuals

        Exclusion Criteria:

          -  Individuals younger than 3 or older than 21 at time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kolevzon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajna Filip-Dhima, MS</last_name>
    <phone>617-919-7068</phone>
    <email>Rajna.Filip-Dhima@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Buckingham</last_name>
      <phone>650-725-0439</phone>
      <email>juliab1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jon Bernstein, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madison Printen</last_name>
      <phone>312-563-3352</phone>
      <email>Madison_T_Printen@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Berry-Kravis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Latha Soorya, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Pekar</last_name>
      <phone>301-402-1084</phone>
      <email>pekarm@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Audrey Thurm, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Carmody</last_name>
      <phone>617-919-4599</phone>
      <email>Erin.Carmody@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Sahin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Durkin</last_name>
      <phone>212-241-2993</phone>
      <email>allison.durkin@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Kolevzon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Avila</last_name>
      <phone>214-648-5155</phone>
      <email>Adrian.Avila@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Powell, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>May 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Mustafa Sahin</investigator_full_name>
    <investigator_title>Assistant in Neurology, Associate Professor of Neurology, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Phelan-McDermid Syndrome</keyword>
  <keyword>PMS</keyword>
  <keyword>Genotype</keyword>
  <keyword>Phenotype</keyword>
  <keyword>Natural History</keyword>
  <keyword>Mapping</keyword>
  <keyword>22q13 Deletion Syndrome</keyword>
  <keyword>SHANK3</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>ASD</keyword>
  <keyword>Intellectual Disability</keyword>
  <keyword>ID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Chromosome Deletion</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
